Cargando…

Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

PURPOSE: Previous research suggests that treatment process can have an influence on patient preference and health state utilities. This study examined preferences and estimated utilities for treatment processes of two daily oral treatment regimens and two weekly injectable regimens for treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matza, Louis S., Cutts, Katelyn N., Stewart, Katie D., Norrbacka, Kirsi, García-Pérez, Luis-Emilio, Boye, Kristina S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233232/ https://www.ncbi.nlm.nih.gov/pubmed/33886044 http://dx.doi.org/10.1007/s11136-021-02808-2

Ejemplares similares

Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
por: Boye, Kristina S., et al.
Publicado: (2019)

Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes
por: Matza, Louis S, et al.
Publicado: (2018)

Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes
por: Matza, Louis S., et al.
Publicado: (2017)

GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data
por: Divino, Victoria, et al.
Publicado: (2019)

GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
por: Divino, Victoria, et al.
Publicado: (2017)

Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes
por: Valentine, William, et al.
Publicado: (2022)

Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)
por: Matza, Louis S., et al.
Publicado: (2018)

Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)
por: Matza, Louis S., et al.
Publicado: (2018)

Development of a Patient-Reported Outcome (PRO) Measure to Assess Emotional Impact of Treatment for Type 2 Diabetes
por: Boye, Kristina S., et al.
Publicado: (2023)

Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis
por: Zimner Rapuch, Sarah, et al.
Publicado: (2021)

Development of a patient-reported outcome (PRO) measure to assess patient perceptions of simplicity and complexity of treatment for type 2 diabetes
por: Stewart, Katie D., et al.
Publicado: (2023)

Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ)
por: Boye, Kristina S., et al.
Publicado: (2020)

Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK
por: Gelhorn, Heather L, et al.
Publicado: (2015)

Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes
por: Smith-Palmer, Jayne, et al.
Publicado: (2016)

Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes
por: Matza, Louis S., et al.
Publicado: (2022)

The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation
por: Matza, Louis S., et al.
Publicado: (2015)

Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments
por: Boye, Kristina S., et al.
Publicado: (2021)

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)
por: Matza, Louis S., et al.
Publicado: (2019)

A qualitative examination of the content validity of the EQ-5D-5L in patients with type 2 diabetes
por: Matza, Louis S., et al.
Publicado: (2015)

Validation of two generic patient-reported outcome measures in patients with type 2 diabetes
por: Matza, Louis S, et al.
Publicado: (2007)

Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study
por: Federici, Marco Orsini, et al.
Publicado: (2018)

Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy
por: Matza, Louis S., et al.
Publicado: (2019)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes
por: Boye, Kristina S., et al.
Publicado: (2020)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

Impact of caregiver and parenting status on time trade-off and standard gamble utility scores for health state descriptions
por: Matza, Louis S, et al.
Publicado: (2014)

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
por: García-Pérez, Luis-Emilio, et al.
Publicado: (2021)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

THU334 Trends In GLP-1 Agonist Utilization In Diabetics With And Without Vascular Disease
por: Sargin, Pinar, et al.
Publicado: (2023)

Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes
por: Thieu, Vivian T, et al.
Publicado: (2019)

Health state utilities associated with treatment for transfusion-dependent β-thalassemia
por: Matza, Louis S., et al.
Publicado: (2019)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Clinical Trial Highlights – GLP-1 agonists
por: McFarthing, Kevin, et al.
Publicado: (2020)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
por: Miñambres, Inka, et al.
Publicado: (2017)

The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy
por: Matza, Louis S, et al.
Publicado: (2008)

An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke
por: Zhang, Huinan, et al.
Publicado: (2016)

The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
por: Antza, Christina, et al.
Publicado: (2019)

Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
por: Kawai, Takahiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o6b8t9ojtmo361pp7oe40nk098